As filed with the Securities and Exchange Commission on August 12, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Astria Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 26-3687168 | |||
| (State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
|
22 Boston Wharf Road, 10th Floor Boston, Massachusetts |
02210 |
|||
| (Address of Principal Executive Offices) | (Zip Code) |
Second Amended and Restated 2015 Stock Incentive Plan
2015 Employee Stock Purchase Plan
2022 Inducement Stock Incentive Plan, as amended
(Full Title of the Plan)
Benjamin Harshbarger
Chief Legal Officer
22 Boston Wharf Road, 10th Floor
Boston, Massachusetts 02210
(Name and Address of Agent For Service)
(617) 349-1971
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ |
| Non-accelerated filer | x | Smaller reporting company | x |
| Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8, relating to the Second Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Astria Therapeutics, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective.
Accordingly, this Registration Statement incorporates by reference the contents of:
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 8. | Exhibits. |
The following exhibits are incorporated herein by reference:
EXHIBIT INDEX
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts, on this 12th day of August, 2024.
| ASTRIA THERAPEUTICS, INC. | ||
| By: | /s/ Jill C. Milne | |
| Jill C. Milne | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Astria Therapeutics, Inc., hereby severally constitute and appoint Jill C. Milne, Benjamin Harshbarger and Noah C. Clauser, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Astria Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||
| /s/ Jill C. Milne |
President and Chief Executive Officer and Director (Principal Executive Officer) |
August 12, 2024 | ||
| Jill C. Milne | ||||
| /s/ Noah Clauser | Chief Financial Officer | August 12, 2024 | ||
| Noah Clauser | (Principal Financial Officer and Principal Accounting Officer) | |||
| /s/ Kenneth Bate | Chairman of the Board of Directors | August 12, 2024 | ||
| Kenneth Bate | ||||
| /s/ Sunil Agarwal | Director | August 12, 2024 | ||
| Sunil Agarwal | ||||
| /s/ Joanne Beck | Director | August 12, 2024 | ||
| Joanne Beck | ||||
| /s/ Frederick P. Callori | Director | August 12, 2024 | ||
| Frederick P. Callori | ||||
| /s/ Hugh Cole | Director | August 12, 2024 | ||
| Hugh Cole | ||||
| /s/ Michael Kishbauch | Director | August 12, 2024 | ||
| Michael Kishbauch | ||||
| /s/ Gregg Lapointe | Director | August 12, 2024 | ||
| Gregg Lapointe | ||||
| /s/ Jonathan Violin | Director | August 12, 2024 | ||
| Jonathan Violin |
Exhibit 5.1
August 12, 2024
Astria Therapeutics, Inc.
22 Boston Wharf Road, 10th Floor
Boston, Massachusetts 02210
| Re: | Registration Statement on Form S-8: Second Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan, as amended |
Ladies and Gentlemen:
We have assisted in the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 6,756,078 shares of common stock, $0.001 par value per share (the “Shares”), of Astria Therapeutics, Inc., a Delaware corporation (the “Company”), issuable under the Company’s Second Amended and Restated 2015 Stock Incentive Plan, 2015 Employee Stock Purchase Plan and 2022 Inducement Stock Incentive Plan, as amended (collectively, the “Plans”).
We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the directors and stockholders of the Company, the Registration Statement and such other documents relating to the Company as we have deemed material for the purposes of this opinion.
In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.
We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or “blue sky” laws.
We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the Commonwealth of Massachusetts, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.
It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
Astria Therapeutics, Inc.
August 12, 2024
Page 2
Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the applicable Plan, the Shares will be validly issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
Very truly yours,
| /s/ WILMER CUTLER PICKERING HALE AND DORR LLP | |
| WILMER CUTLER PICKERING HALE AND DORR LLP |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Second Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Astria Therapeutics, Inc. of our report dated March 4, 2024, with respect to the consolidated financial statements of Astria Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Boston, Massachusetts
August 12, 2024
Exhibit 107
Calculation of Filing Fee Tables
| Form S-8 |
| (Form Type) |
| Astria Therapeutics, Inc. |
| (Exact Name of Registrant as Specified in its Charter) |
Table 1—Newly Registered Securities
| Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee |
||||||||||||
| Equity(2) | Common Stock, $0.001 par value per share | Other(3) | 6,756,078 shares(2) | $ | 9.59 | (3) | $ | 64,790,788.02 | (3) | $147.60 per $1,000,000 |
$ | 9,563.12 | |||||||
| Total Offering Amounts | $ | 64,790,788.02 | $ | 9,563.12 | |||||||||||||||
| Total Fee Offsets | — | ||||||||||||||||||
| Net Fee Due | $ | 9,563.12 | |||||||||||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
| (2) | Consists of (i) 5,750,000 shares issuable under the Second Amended and Restated 2015 Stock Incentive Plan, (ii) 6,078 shares issuable under the 2015 Employee Stock Purchase Plan, and (iii) 1,000,000 shares issuable under the 2022 Inducement Stock Incentive Plan, as amended. |
| (3) | The proposed maximum offering price per share of $9.59 is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act and is based upon the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Market on August 5, 2024. |